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Abstract: Herein we report the first example of an
isoDGR–drug conjugate (2), designed to release paclitaxel
selectively within cancer cells expressing integrin aVb3.
Conjugate 2 was synthesized by connecting the isoDGR
peptidomimetic 5 with paclitaxel via the lysosomally
cleavable Val–Ala dipeptide linker. Conjugate 2 displayed
a low nanomolar affinity for the purified integrin aVb3 re-
ceptor (IC50=11.0 nm). The tumor targeting ability of con-
jugate 2 was assessed in vitro in anti-proliferative assays
on two isogenic cancer cell lines characterized by different
integrin aVb3 expression: human glioblastoma U87
(aVb3+) and U87 b3-KO (aVb3@). The isoDGR-PTX conju-
gate 2 displayed a remarkable targeting index (TI=9.9),
especially when compared to the strictly related RGD-PTX
conjugate 4 (TI=2.4).
Nowadays, the development of molecular devices able to se-
lectively deliver chemotherapeutics at the disease site has
gained a central position in cancer research. In particular, such
targeting agents would allow circumventing the lack of selec-
tivity observed when administering cytotoxic agents to pa-
tients. Due to this main limitation, traditional chemotherapy re-
quires the use of high drug dosages, with consequent severe
side effects that vitiate the overall efficacy of the therapy.[1] A
first approach consisted in the preparation of antibody–drug
conjugates (ADCs), in which the use of monoclonal antibodies
(mAbs) to target specific tumor antigens resulted in a clear dis-
crimination of cancer cells from healthy tissues. However, this
strategy presents several drawbacks, especially related to high
manufacturing costs, poor pharmacokinetic properties and
possible immune-system-induced alteration of drug efficien-
cy.[2] At this stage, small molecule–drug conjugates (SMDCs)
arose as an alternative to ADCs: in this case, the targeting
moiety is a small molecule, such as an oligopeptide, a peptido-
mimetic or a vitamin, capable of interacting selectively with
particular proteins overexpressed by tumor cells. Unlike ADCs,
the use of a small molecule ascribes improved pharmacokinet-
ic properties to the entire conjugate, which in principle can be
synthesized by easier and more affordable synthetic strat-
egies.[2]
In the field of SMDCs, integrin aVb3 represents a very inter-
esting target to be exploited for the selective delivery of anti-
cancer agents within the tumor site. As matter of fact, the ex-
pression of this transmembrane receptor is increased in a varie-
ty of human cancer types (e.g. , breast cancer, glioblastoma,
pancreatic tumor, prostate carcinoma) with respect to healthy
tissues. The increased expression of aVb3 integrin in tumor cells
is associated with different pathological features: angiogenesis,
tumor growth, apoptosis resistance, and metastasis.[3] Integrin
aVb3 recognizes endogenous ligands by the tripeptide argi-
nine-glycine-aspartate[4] (RGD) and also by the related se-
quence iso-aspartate-glycine-arginine[5, 6] (isoDGR). In 2012,
computational and biochemical studies showed that isoDGR-
containing cyclopeptides act as genuine aVb3 antagonists,
blocking the ligand binding site and inhibiting integrin alloste-
ric activation.[6a] In contrast to the RGD ligands which in some
cases may cause adverse paradoxical integrin activation effect-
s,[6a,7] compounds based on the isoDGR motif could become
a new generation of integrin-binding drugs free from these
drawbacks. For example, isoDGR ligand 1 (Figure 1) displays in-
hibitory effects on the FAK/Akt integrin-activated transduction
pathway and on integrin-mediated cell infiltration processes,
qualifying therefore as a true integrin antagonist.[8]
A variety of ligands containing the RGD sequence have been
synthesized and reported in the literature so far, with some of
them showing a very high affinity for the integrin receptor.[9]
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Moreover, numerous RGD–drug conjugates have been devel-
oped for tumor targeting in the past two decades,[10–12] while
no example of isoDGR–drug conjugate has ever been reported.
In fact, compared to the high binding affinity of the RGD li-
gands for aVb3 integrin (IC50<15 nm),
[9] the isoDGR motif dis-
played much lower affinity (IC50+43 nm),[13] with a single nota-
ble exception (1, IC50=9.2 nm), see Figure 1.
[8]
Herein we report the first example of an isoDGR–drug conju-
gate (2, Figure 1), based on ligand 1, which displays a high
binding affinity for the purified integrin aVb3 receptor (IC50=
11.0 nm), see Table 1.
Conjugate 2 has been designed in a way similar to the cor-
responding RGD-drug conjugate (4, Figure 1),[10g] which con-
tains the RGD integrin ligand 3.[14] The isoDGR targeting
moiety has been linked to the cytotoxic agent paclitaxel using
the lysosomally cleavable dipeptide Val–Ala: this sequence
showed high plasma stability, whereas it is rapidly cleaved by
lysosomal cysteine proteases (such as cathepsins B and D)
upon integrin-mediated internalization by endocytosis.[10g,15,16]
In order to synthesize conjugate 2, first we prepared pepti-
domimetic 5 (Scheme 1), a derivative of the isoDGR ligand
1 bearing an amino functional group suitable for conjugation.
Bifunctional diketopiperazine 6[10h] was Boc-deprotected and
reacted with Cbz-Arg(Mtr) to give carboxylic acid 9 upon allyl
ester cleavage. Acid 9 was coupled with dipeptide 13, ob-
tained starting from protected aspartic acid 10 (commercially
available) and benzyl glycinate 11. The benzyl (Bn) and carbox-
ybenzyl (Cbz) protecting groups of the resulting compound 14
were selectively removed by catalytic hydrogenolysis to afford
amino acid 15, which was cyclized under high dilution condi-
tions (1.4 mm). Mtr- (4-methoxy-2,3,6-trimethylbenzenesul-
phonyl) and tert-butyl ester removal on macrolactam 16 afford-
ed the desired isoDGR peptidomimetic 5 after HPLC purifica-
tion and freeze-drying. The benzylic amine of compound 5
Figure 1. Structures of the integrin ligands cyclo[DKP-isoDGR] (1) and cy-
clo[DKP-RGD] (3), and of the corresponding SMDCs cyclo[DKP-isoDGR]-Val-
Ala-PTX (2) and cyclo[DKP-RGD]-Val-Ala-PTX (4).
Table 1. Inhibition of biotinylated vitronectin binding to purified aVb3 re-
ceptor.
Entry Ligand Structure aVb3 IC50 [nm]
[a]
1 1 cyclo[DKP-isoDGR] 9.2:1.1
2 2 cyclo[DKP-isoDGR]-Val-Ala-PTX 11.0:0.2
3 3 cyclo[DKP-RGD] 4.5:1.1
4 4 cyclo[DKP-RGD]-Val-Ala-PTX 13.3:3.6
[a] IC50 values were calculated as the concentration of compound re-
quired for 50% inhibition of biotinylated vitronectin binding. Screening
assays were performed by incubating the immobilized integrin aVb3 with
increasing concentrations (10@12–10@5m) of the RGD or isoDGR ligands in
the presence of biotinylated vitronectin (1 mgmL@1), and measuring the
concentration of bound vitronectin in the presence of the competitive li-
gands.
Scheme 1. Synthesis isoDGR peptidomimetic 5. Reagents and conditions: a) TFA/CH2Cl2 1:2, RT, 2 h; b) Cbz-Arg(Mtr)-OH, HATU, HOAt, iPr2NEt, DMF, 0 8C to RT,
overnight, 94% over 2 steps; c) [Pd(PPh3)4] , N-methylaniline, CH2Cl2, 0 8C, 1 h, 88%; d) HATU, HOAt, iPr2NEt, DMF, 0 8C to RT, overnight, 86%; e) piperidine,
DMF, 2 h, RT, 67%; f) 13, HATU, HOAt, iPr2NEt, DMF, 0 8C to RT, overnight, 95%; g) H2, 10% Pd/C, THF/H2O 1:1, overnight, RT, 95%; h) HATU, HOAt, iPr2NEt,
DMF/CH2Cl2 1:1 (1.4 mm), 0 8C to RT, overnight, 79%; i) TFA/TMSBr/thioanisole/EDT/phenol 70:14:10:5:1, 2 h, RT, 47%. (TFA= trifluoroacetic acid, HATU=1-[Bis(-
dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, TMSBr=bromotrimethylsilane, EDT=1,2-ethanedithiol).
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was coupled with 18, the N-hydroxysuccinimidyl ester of car-
boxylic acid 17,[10g] to give compound 19 (Scheme 2). Treat-
ment of 19 with trifluoroacetic acid in dichloromethane afford-
ed amine 20 which was reacted with carbonate 22 to obtain
the final isoDGR-PTX conjugate 2.
The tumor-targeting ability of conjugate 2 was assessed in
vitro against two isogenic cancer cell lines characterized by dif-
ferent integrin aVb3 expression. U87 human glioblastoma cells
were selected as the integrin aVb3-expressing cell line and, at
the same time, used to generate the corresponding clone U87
b3-KO, in which the expression of the gene encoding for the b3
integrin subunit was deleted using CRISPR-Cas9 gene editing
technology.[17] Flow cytometry studies on U87 and U87 b3-KO
cells confirmed the absence of integrin aVb3 in the U87 b3-KO
cell line (Figure 2).
Clone U87 b3-KO is not a perfect negative control, as the
conjugates can still be actively internalized upon interaction
with other integrins, for example, aVb5. Therefore, the selectivi-
ty shown by the conjugates in cell viability experiments using
U87 b3-KO and U87 cells [IC50(aVb3@)/IC50(aVb3+)] should be
considered as a minimum (conservative) value.[18] Cells were in-
cubated with increasing doses of isoDGR–PTX conjugate 2 for
144 h, before measuring the cell viability in culture (Table 2).
Parallel experiments were performed under the same condi-
tions with the RGD–PTX conjugate 4 (Figure 1) and paclitaxel
(PTX, 21). Paclitaxel itself appeared to be 2.3 times more effec-
tive on U87 b3-KO cells, possibly because the b3-integrin-de-
pleted cells divide faster. Taking into account the intrinsic se-
lectivity shown by free paclitaxel, the isoDGR–PTX conjugate 2
displayed a remarkable targeting effect (TI=9.9), especially
when compared to the strictly related RGD–PTX conjugate 4
(TI=2.4). Apparently, the isoDGR-PTX conjugate 2 is recog-
nized more specifically by integrin aVb3 than the related RGD-
PTX conjugate 4 which can be effectively internalized also by
other integrins expressed on the cell surface.
Scheme 2. Synthesis of isoDGR–drug conjugate 2. Reagents and conditions: a) DIC, NHS, DMF, 0 8C to RT, overnight; b) 5, CH3CN/PBS 1:1; pH 7.3–7.6, 0 8C to
RT, overnight; c) TFA/CH2Cl2 1:2, 1 h, RT, 55% over three steps; d) 4-Nitrophenylchloroformate, pyridine, CH2Cl2, @50 8C to @20 8C; 4 h, 69%; e) 22, iPr2NEt,
DMF, 0 8C to RT, overnight, 55%. (PBS=phosphate-buffered saline).
Figure 2. Flow cytometry experiments on U87 and U87 b3-KO cells to assess
the different aVb3 integrin expression. Cells were incubated with the secon-
dary antibody (CF488A-goat anti-mouse IgG, Biotium 20011), or with the
anti-aVb3 antibody (clone LM609-Millipore MAB 1976) followed by the secon-
dary antibody, see the Supporting Information.
Table 2. Evaluation of anti-proliferative activity of isoDGR-PTX conjugate
2 in U87 and U87 b3-KO.
Structure IC50 [nm]
[a] TI[b]
U87 (aVb3+) U87 b3-KO (aVb3@)
Paclitaxel (21) 0.64 0.28 1
isoDGR-PTX conjugate (2) 927.6 4003.0 9.9
RGD-PTX conjugate (4) 550.0 581.7 2.4
[a] IC50 values were calculated as the concentration of compound re-
quired for 50% inhibition of cell viability in culture, based on quantitation
of the ATP present as estimated by CellTiter-GLO; cells were treated for
144 h in 96-well plates. [b] Targeting index (TI): [IC50(aVb3@)/
IC50(aVb3+)]conjugate/[IC50(aVb3@)/IC50(aVb3+)]paclitaxel.
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In conclusion, the first isoDGR–drug conjugate (2) has been
developed for tumor targeting. Compound 2 displayed a low
nanomolar affinity for the purified integrin aVb3 receptor and
a notable targeting ability when tested on two isogenic cancer
cell lines expressing integrin aVb3 at different levels. Fine
tuning of the linker[19] is in progress in order to improve the
potency of the conjugate while retaining the high selectivity.
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